# **Department of Fiscal Services**

Maryland General Assembly

#### FISCAL NOTE

Senate Bill 359 (Senator Blount) Economic and Environmental Affairs

### **Health Occupations - State Board of Pharmacy**

This bill alters provisions relating to the waiver of examination requirements for pharmacy license applicants who are licensed in another state. The bill requires the Board of Pharmacy to adopt, by regulation, an examination for such applicants.

In addition, the bill alters license renewal provisions by specifying that a license expires on the date set by the board unless renewed for an additional term. A license may not be renewed for a term longer than two years.

The board is required to adopt regulations to govern the transition to the new expiration date for licenses, as specified.

## **Fiscal Summary**

**State Effect:** Indeterminate effect on Board of Pharmacy Fund revenues as discussed below. Expenditures would not be affected.

Local Effect: None.

### **Fiscal Analysis**

**State Revenues:** The Board of Pharmacy reports that they have not yet devised a new plan for license renewals. However, the board believes that any new period they would set for renewals would only affect the timing of license renewal income, and not affect overall collections.

Fiscal Services advises that any transition period could have a measurable affect on Board of Pharmacy Fund revenues for the fiscal years affected. That is, while the overall collections of renewal license fees might remain the same (over time), the duration of a transition period could reduce revenues in one fiscal year and correspondingly increase revenues in a succeeding year. Without knowing when these revenues would be collected, Fiscal Services finds it difficult to quantify the special fund revenue effect of the bill at this time.

**Information Source(s):** Department of Health and Mental Hygiene (Board of Pharmacy), Department of Fiscal Services

**Fiscal Note History:** First Reader - February 19, 1996

ncs

Analysis by: Guy Cherry Direct Inquiries to:

Reviewed by: John Rixey John Rixey, Coordinating Analyst

(410) 841-3710 (301) 858-3710